Page Banner

United States Department of Agriculture

Agricultural Research Service

Title: The effect of AlloDerm® on the initiation and growth of human neovessels.)

Author
item Weiss, Sean
item Tenney, Justin
item Thomson, Jessica
item Anthony, Catherine
item Chiu, Ernest
item Friedlander, Paul
item Woltering, Eugene

Submitted to: The Laryngoscope
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 7/10/2009
Publication Date: 3/1/2010
Citation: Weiss, S.R., Tenney, J.M., Thomson, J.L., Anthony, C.T., Chiu, E.S., Friedlander, P.L., Woltering, E.A. 2010. The effect of AlloDerm® on the initiation and growth of human neovessels. The Laryngoscope. 120(3):443-449.

Interpretive Summary: AlloDerm®, a matrix of natural biological components, has been used in the reconstruction of head and neck defects following surgery. The potential for AlloDerm® to stimulate new blood vessel growth, and thus, enhance wound healing, is unknown. In this study, we tested the effects of AlloDerm® alone, and AlloDerm® plus two different blood products using a model to simulate a healing wound. We found that AlloDerm® alone actually decreased new blood vessel growth (contrary to our belief). However, AlloDerm® plus one of the blood products did increase new blood vessel growth. Hence, AlloDerm® enriched with a blood product may enhance wound healing, although further studies are needed to confirm our results.

Technical Abstract: AlloDerm® is commonly employed for reconstruction of ablative soft tissue and mucosal defects following surgical resections. Although devoid of growth factors, AlloDerm® may serve as an adhesive matrix for binding of growth factors increasing local angiogenesis and wound healing. We hypothesized that AlloDerm® would enhance angiogenesis, and might be altered with autologous blood products to enhance initiation of the angiogenic response. We used a human placental vein in a fibrin-thrombin clot based angiogenesis model. Four groups, human placental vein (HPVM), HPVM with AlloDerm®, HPVM with AlloDerm® plus platelet poor plasma (PPP), and HPVM with AlloDerm® plus platelet rich plasma (PRP) were evaluated. Endothelial cell growth was evaluated visually (40x). Hematoxylin and eosin staining, and immunofluorescent staining for growth within the AlloDerm® matrix were also performed. To assess human umbilical vein endothelial cell (HUVEC) sites of attachment to AlloDerm®, we incubated HUVEC cells with AlloDerm® for a period of 2 weeks and evaluated attachment with anti-factor 8 immunofluorescence. Angiogenic initiation decreased in the combined placental vein with AlloDerm® group (p-value<.0001 at day 7, 14, 21). Additionally, initiation in the AlloDerm® + PPP group was significantly better than the AlloDerm® alone group when placentas 2 and 3 were compared (p-value < .0001). On hematoxylin and eosin staining, as well as immunofluorescent factor 8 staining, no endothelial growth into the AlloDerm® was noted in the samples analyzed. AlloDerm® may be enriched with platelet poor plasma to stimulate greater initiation and wound healing, however, AlloDerm® inhibits angiogenic initiation in this model.

Last Modified: 8/24/2016
Footer Content Back to Top of Page